Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Expects Revenue From Molecular Dx to Be Between $23M and $26M in 2005

NEW YORK, Nov. 11 (GenomeWeb News) - Third Wave Technologies expects revenues from clinical molecular diagnostic products to expand to between $23 million and $26 million in 2005, the company said today.

The company said the revenue will be "driven chiefly by the company's core genetics, cystic fibrosis and HCV genotyping reagents."

 

The company this morning scheduled a conference call to detail expansion of its molecular diagnostic product development efforts to move the company past the core SNP detection technology products market it serves with its Invader-brand chemistry.

 

Third Wave generated $36.3 million in 2003. The company does not break down revenues for its molecular diagnostics business.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.